EA200401124A1 - Аминозамещённые (e)-2,6-диалкоксистирил-4-замещённые-бензилсульфоны для лечения пролиферативных расстройств - Google Patents

Аминозамещённые (e)-2,6-диалкоксистирил-4-замещённые-бензилсульфоны для лечения пролиферативных расстройств

Info

Publication number
EA200401124A1
EA200401124A1 EA200401124A EA200401124A EA200401124A1 EA 200401124 A1 EA200401124 A1 EA 200401124A1 EA 200401124 A EA200401124 A EA 200401124A EA 200401124 A EA200401124 A EA 200401124A EA 200401124 A1 EA200401124 A1 EA 200401124A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted
dialoxystyl
benzilsulphones
amino
treatment
Prior art date
Application number
EA200401124A
Other languages
English (en)
Other versions
EA008736B1 (ru
Inventor
Премкумар Э. Редди
Рамана М. В. Редди
Стэнли К. Белл
Original Assignee
Темпл Юниверсити-Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн
Онконова Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Темпл Юниверсити-Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн, Онконова Терапьютикс, Инк. filed Critical Темпл Юниверсити-Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн
Publication of EA200401124A1 publication Critical patent/EA200401124A1/ru
Publication of EA008736B1 publication Critical patent/EA008736B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Abstract

Предлагаются соединения формулы (I), полезные в качестве антипролиферативных средств, включая, например, противораковые средства, где X, X, X, R, R, R, R, R, R, R, R, g, M, y, a, b, d, e, V, W, Z и Q являются такими, как определено в настоящем описании.Отчет о международном поиске был опубликован 2003.12.04.
EA200401124A 2002-02-28 2003-02-28 Аминозамещенные (e)-2,6-диалкоксистирил-4-замещенные-бензилсульфоны для лечения пролиферативных расстройств EA008736B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36069702P 2002-02-28 2002-02-28
PCT/US2003/006357 WO2003072062A2 (en) 2002-02-28 2003-02-28 Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders

Publications (2)

Publication Number Publication Date
EA200401124A1 true EA200401124A1 (ru) 2005-02-24
EA008736B1 EA008736B1 (ru) 2007-08-31

Family

ID=27766240

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401124A EA008736B1 (ru) 2002-02-28 2003-02-28 Аминозамещенные (e)-2,6-диалкоксистирил-4-замещенные-бензилсульфоны для лечения пролиферативных расстройств

Country Status (13)

Country Link
US (2) US7598232B2 (ru)
EP (1) EP1487428B1 (ru)
JP (1) JP4588323B2 (ru)
KR (1) KR100972131B1 (ru)
AT (1) ATE525067T1 (ru)
AU (1) AU2003213660C1 (ru)
CA (1) CA2477232C (ru)
EA (1) EA008736B1 (ru)
ES (1) ES2373945T3 (ru)
IL (2) IL163607A0 (ru)
MX (1) MXPA04008356A (ru)
NZ (1) NZ535232A (ru)
WO (1) WO2003072062A2 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163608A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
IL163607A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted 2,6-dialkoxystyryl 4-substitutedbenzylsulfones for treating proliferative disorders
WO2005046599A2 (en) * 2003-11-14 2005-05-26 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
EA200901236A1 (ru) * 2004-03-16 2009-12-30 Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн Замещённые фенокси- и фенилтиопроизводные для лечения пролиферативных нарушений
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
ATE529106T1 (de) 2004-06-24 2011-11-15 Univ Temple Alpha-, beta-ungesättigte sulfone, sulfonoxide, sulfonimide, sulfinimide, acylsulfonamide und acylsulfinamide und therapeutische verwendungen damit
DE602005026293D1 (de) * 2004-07-19 2011-03-24 Onconova Therapeutics Inc Formulierungen für die parenterale verabreichung von (e)-2,6-dialkoxystryryl 4-substituierten benzylsulfonen
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
KR101427105B1 (ko) * 2005-01-05 2014-08-07 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 약-내성 증식성 질병의 치료
US8106033B2 (en) * 2005-03-11 2012-01-31 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2007002441A1 (en) * 2005-06-24 2007-01-04 Emory University Methods of use for non-atp competitive tyrosine kinase inhibitors to treat pathogenic infection
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
WO2008006884A2 (en) 2006-07-13 2008-01-17 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
US8664272B2 (en) 2006-08-30 2014-03-04 Temple University—Of the Commonwealth System of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
WO2008033475A2 (en) * 2006-09-15 2008-03-20 Onconova Therapeutics, Inc. Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions
EP2124569A4 (en) * 2007-01-16 2013-02-27 Onconova Therapeutics Inc FORMULATIONS FOR THE PARENTERAL ADMINISTRATION OF (E) -2,6-DIALKOXY STYRYL-4-SUBSTITUTED BENZYL SULPHONES
DK2185562T3 (en) 2007-07-27 2016-02-22 Janssen Pharmaceutica Nv PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
JP2012512223A (ja) 2008-12-18 2012-05-31 エフ．ホフマン−ラ ロシュ アーゲー チアゾリル−ベンズイミダゾール類
GB201010359D0 (en) * 2010-06-21 2010-08-04 Univ Nottingham Compounds for treating proliferative disorders
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
CN110776447A (zh) 2012-09-20 2020-02-11 坦普尔大学 取代的烷基二芳基衍生物、制备方法和用途
ES2864681T3 (es) 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer
WO2017023912A1 (en) 2015-08-03 2017-02-09 Temple University - Of The Commonwealth System Of Higher Education 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use
WO2018169283A1 (ko) 2017-03-14 2018-09-20 국립암센터 C형 간염 바이러스 질환 치료를 위한 리고세르팁의 신규 용도
WO2018190897A1 (en) 2017-04-13 2018-10-18 Onconova Therapeutics, Inc. Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4- methoxybenzylsulphone with enhanced stability and bioavailability
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
WO2020086789A1 (en) 2018-10-26 2020-04-30 Teva Pharmaceuticals International Gmbh New crystalline polymorphs of rigosertib sodium
CA3132656A1 (en) 2019-04-30 2020-11-05 Instituto De Medicina Molecular Joao Lobo Antunes Rank pathway inhibitors in combination with cdk inhibitors
CN110981770A (zh) * 2019-12-30 2020-04-10 武汉九州钰民医药科技有限公司 制备抗肿瘤新药Rigosertib的方法
CN114539110B (zh) * 2020-11-26 2023-02-14 东南大学 含有ras/raf蛋白干扰基团的hdac抑制剂及其制备方法
TW202404636A (zh) 2022-04-08 2024-02-01 美商英伊布里克斯公司 Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2532612A (en) * 1945-08-29 1950-12-05 Union Oil Co Preparation of unsaturated thio-ethers
US2531367A (en) * 1947-07-15 1950-11-21 Sharp & Dohme Inc N-(substituted sulfonyl)-aminobenzoic acids
US3185743A (en) * 1960-08-24 1965-05-25 Union Carbide Corp Production of olefinic compounds from allyl sulfones
US3463774A (en) * 1963-03-18 1969-08-26 Hoffmann La Roche Novel 4,1-benzothiazepin-2-(1h)-ones and 4,1-benzothiazepines
US3418101A (en) * 1965-12-15 1968-12-24 Pennsalt Chemicals Corp Process for plant desiccation
US3514386A (en) * 1967-12-11 1970-05-26 Exxon Research Engineering Co Stereoselective addition of thiols to acetylenic compounds
US3917714A (en) * 1972-09-06 1975-11-04 American Cyanamid Co Bis(alkylsulfonyl)vinylbenzenes
US4161407A (en) * 1977-10-06 1979-07-17 Eastman Kodak Company Crosslinkable polymers having vinylsulfonyl groups or styrylsulfonyl groups and their use as hardeners for gelatin
DE2809377A1 (de) * 1978-03-04 1979-09-13 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4386221A (en) * 1981-10-28 1983-05-31 Eastman Kodak Company Process for the preparation of aryl alkyl sulfones and aryl vinyl sulfones
US4937388A (en) * 1985-08-09 1990-06-26 Imperial Chemical Industries Plc Insecticidal ethers
JPH04202173A (ja) 1990-11-30 1992-07-22 Zeria Pharmaceut Co Ltd スルホンアミド誘導体及びそれを含有する５―リポキシゲナーゼ阻害剤
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
AU6112896A (en) 1995-06-07 1996-12-30 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell prolifer ative disorders or cell differentiation disorders
US5659087A (en) * 1995-06-07 1997-08-19 Eli Lilly And Company Diarylvinyl sulfoxides
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
CZ299718B6 (cs) * 1997-10-03 2008-10-29 Temple University - Of The Commonwealth System Ofhigher Education Styrylsulfonová sloucenina a farmaceutický prostredek ji obsahující
US6548553B2 (en) * 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
US6191170B1 (en) * 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
JP2002541101A (ja) * 1999-04-02 2002-12-03 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション スチリルスルホン抗癌剤
US6762207B1 (en) * 1999-04-02 2004-07-13 Temple University - Of The Commonwealth System Of Higher Education (E)-styryl sulfone anticancer agents
EP1173160B1 (en) * 1999-04-02 2005-06-22 Temple University of the Commonwealth System of Higher Education (e)-styryl sulfone anticancer agents
US6586617B1 (en) * 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
US6767926B1 (en) * 1999-10-12 2004-07-27 Temple University - Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
JP4780885B2 (ja) * 1999-10-12 2011-09-28 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 正常細胞を化学療法剤の細胞毒性から保護するための方法
US6462207B1 (en) * 1999-10-13 2002-10-08 Southwest Missouri State University Polyethylene glycol diene derivatives
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
CA2424884C (en) * 2000-10-05 2009-12-15 E. Premkumar Reddy Substituted (e)-styryl benzylsulfones for treating proliferative disorders
WO2002067913A1 (en) * 2001-02-27 2002-09-06 Temple University-Of The Commonwealth System Of Higher Education (z)-styrylbenzylsulfones and pharmaceutical uses thereof
JP4302986B2 (ja) * 2001-02-28 2009-07-29 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 細胞及び組織をα，β不飽和アリールスルホンにより電離放射線から防護する方法
KR100850330B1 (ko) * 2001-02-28 2008-08-04 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Ｎ-(아릴)-2-아릴에텐술폰아미드 및 이를 이용한 약학적 조성물
IL163607A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted 2,6-dialkoxystyryl 4-substitutedbenzylsulfones for treating proliferative disorders
IL163608A0 (en) * 2002-02-28 2005-12-18 Univ Temple Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders

Also Published As

Publication number Publication date
EP1487428A2 (en) 2004-12-22
KR20040091676A (ko) 2004-10-28
US8324190B2 (en) 2012-12-04
CA2477232A1 (en) 2003-09-04
AU2003213660A1 (en) 2003-09-09
EP1487428B1 (en) 2011-09-21
AU2003213660C1 (en) 2010-10-28
EA008736B1 (ru) 2007-08-31
ES2373945T3 (es) 2012-02-10
US20050130942A1 (en) 2005-06-16
AU2003213660B2 (en) 2010-04-22
IL163607A (en) 2012-07-31
IL163607A0 (en) 2005-12-18
US20090281066A1 (en) 2009-11-12
MXPA04008356A (es) 2005-09-12
US7598232B2 (en) 2009-10-06
JP4588323B2 (ja) 2010-12-01
WO2003072062A3 (en) 2003-12-04
NZ535232A (en) 2007-05-31
WO2003072062A2 (en) 2003-09-04
EP1487428A4 (en) 2006-04-19
JP2005531503A (ja) 2005-10-20
CA2477232C (en) 2011-07-19
KR100972131B1 (ko) 2010-07-26
ATE525067T1 (de) 2011-10-15

Similar Documents

Publication Publication Date Title
EA200401124A1 (ru) Аминозамещённые (e)-2,6-диалкоксистирил-4-замещённые-бензилсульфоны для лечения пролиферативных расстройств
DK1836201T3 (da) Pyrrolidininhibitorer af IAP
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
NO20062357L (no) Indolinderivater og anvendelse av dem ved behandling av sykdomstilstander som cancer
MY140767A (en) Compounds, methods and compositions
SE9900100D0 (sv) New compounds
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
MY140169A (en) Compounds, compositions, and methods
MY138737A (en) N3-substituted imidazopyridine c-kit inhibitors
NO20054494L (no) Peptidvektorer
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
DE60326248D1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
ATE516031T1 (de) Verbindungen gegen krebs
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DK1362045T3 (da) 2-Thio-substituerede imidazolderivater og deres anvendelse inden for farmacien
EA200400117A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов, обладающие антивирусной активностью, способ их получения (варианты) и способ лечения вирусной инфекции
DE60315288D1 (de) Cyanoguanidin prodrugs
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
TW200503722A (en) Substituted 7-aza-quinazoline compounds
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
DK1455770T3 (da) Anvendelse af norepinephringenoptagelsesinhibitorer til behandling af tic lidelser
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens